Literature DB >> 32928995

Role of peripheral sensory neuron mu-opioid receptors in nociceptive, inflammatory, and neuropathic pain.

Awinita Barpujari1, Neil Ford1, Shao-Qiu He1, Qian Huang1, Claire Gaveriaux-Ruff2, Xinzhong Dong3,4,5,6,7, Yun Guan1,4, Srinivasa Raja8,3.   

Abstract

BACKGROUND AND
OBJECTIVE: The role of peripheral mu-opioid receptors (MOPs) in chronic pain conditions is not well understood. Here, we used a combination of mouse genetics, behavioral assays, and pharmacologic interventions to investigate the contribution of primary afferent MOPs to nociceptive, inflammatory, and neuropathic pain, as well as to opioid analgesia.
METHODS: We generated conditional knockout mice in which MOPs were selectively deleted in primary sensory neurons. Inflammatory and neuropathic pain states were induced in mutant and control wild-type mice and their behavioral responses to noxious stimuli were compared. Gross motor function was also evaluated. Immunohistochemistry was used to assess MOP expression in the dorsal root ganglia, periaqueductal gray, and small intestine. The effects of MOP agonists DALDA (dermorphin [D-Arg2, Lys4] (1-4) amide) and morphine were evaluated in pain behavior assays, and their effects on neuronal physiology in the dorsal root ganglia were evaluated in whole-cell patch-clamp recordings.
RESULTS: Conditional MOP knockouts and control mice exhibited similar behavioral responses to acute nociceptive stimuli and developed similar inflammation-induced hypersensitivity. Unilateral nerve injury in animals lacking peripheral MOPs induced enhanced, bilateral mechanical allodynia. Subcutaneously administered DALDA was unable to decrease the hypersensitivity induced by inflammation and nerve injury in MOP knockout animals, and morphine's antinociceptive effects were significantly attenuated in the absence of peripheral MOPs.
CONCLUSION: MOPs in primary sensory neurons contribute to the modulation of neuropathic pain behavior and opioid analgesia. Our observations highlight the clinical potential of peripherally acting opioid agonists in the management of inflammatory and neuropathic pain. © American Society of Regional Anesthesia & Pain Medicine 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  analgesics; chronic pain; drug-related side effects and adverse reactions; neuralgia; opioid; pain management

Mesh:

Substances:

Year:  2020        PMID: 32928995      PMCID: PMC8692009          DOI: 10.1136/rapm-2020-101779

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  30 in total

1.  The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors.

Authors:  Biao Xu; Mengna Zhang; Xuerui Shi; Run Zhang; Dan Chen; Yong Chen; Zilong Wang; Yu Qiu; Ting Zhang; Kangtai Xu; Xiaoyu Zhang; Wolfgang Liedtke; Rui Wang; Quan Fang
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

2.  Oligomerization of MrgC11 and μ-opioid receptors in sensory neurons enhances morphine analgesia.

Authors:  Shao-Qiu He; Qian Xu; Vinod Tiwari; Fei Yang; Michael Anderson; Zhiyong Chen; Shaness A Grenald; Srinivasa N Raja; Xinzhong Dong; Yun Guan
Journal:  Sci Signal       Date:  2018-06-19       Impact factor: 8.192

3.  Bilateral and differential changes in spinal mu, delta and kappa opioid binding in rats with a painful, unilateral neuropathy.

Authors:  Craig W Stevens; Keith C Kajander; Gary J Bennett; Virginia S Seybold
Journal:  Pain       Date:  1991-09       Impact factor: 6.961

4.  Neuron-restrictive silencer factor causes epigenetic silencing of Kv4.3 gene after peripheral nerve injury.

Authors:  H Uchida; K Sasaki; L Ma; H Ueda
Journal:  Neuroscience       Date:  2009-12-13       Impact factor: 3.590

5.  Peripherally Acting μ-Opioid Receptor Agonists Attenuate Ongoing Pain-associated Behavior and Spontaneous Neuronal Activity after Nerve Injury in Rats.

Authors:  Vinod Tiwari; Michael Anderson; Fei Yang; Vineeta Tiwari; Qin Zheng; Shao-Qiu He; Tong Zhang; Bin Shu; Xueming Chen; Shaness A Grenald; Kimberly E Stephens; Zhiyong Chen; Xinzhong Dong; Srinivasa N Raja; Yun Guan
Journal:  Anesthesiology       Date:  2018-06       Impact factor: 7.892

6.  Mu and delta opioid receptors play opposite nociceptive and behavioural roles on nerve-injured mice.

Authors:  Miriam Martínez-Navarro; David Cabañero; Agnieszka Wawrzczak-Bargiela; Anne Robe; Claire Gavériaux-Ruff; Brigitte L Kieffer; Ryszard Przewlocki; Josep E Baños; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2020-02-10       Impact factor: 8.739

Review 7.  Advances in Achieving Opioid Analgesia Without Side Effects.

Authors:  Halina Machelska; Melih Ö Celik
Journal:  Front Pharmacol       Date:  2018-11-29       Impact factor: 5.810

8.  Identification of a bilirubin receptor that may mediate a component of cholestatic itch.

Authors:  James Meixiong; Chirag Vasavda; Dustin Green; Qin Zheng; Lijun Qi; Shawn G Kwatra; James P Hamilton; Solomon H Snyder; Xinzhong Dong
Journal:  Elife       Date:  2019-01-21       Impact factor: 8.140

9.  Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice.

Authors:  Raphaël Weibel; David Reiss; Laurie Karchewski; Olivier Gardon; Audrey Matifas; Dominique Filliol; Jérôme A J Becker; John N Wood; Brigitte L Kieffer; Claire Gaveriaux-Ruff
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

10.  Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions.

Authors:  Katerina S Iwaszkiewicz; Jennifer J Schneider; Susan Hua
Journal:  Front Pharmacol       Date:  2013-10-24       Impact factor: 5.810

View more
  1 in total

1.  Role of primary sensory neurone cannabinoid type-1 receptors in pain and the analgesic effects of the peripherally acting agonist CB-13 in mice.

Authors:  Neil C Ford; Awinita Barpujari; Shao-Qiu He; Qian Huang; Chi Zhang; Xinzhong Dong; Yun Guan; Srinivasa N Raja
Journal:  Br J Anaesth       Date:  2021-11-26       Impact factor: 11.719

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.